timberland earth Cleveland Clinic announces top 10 innovations of 2018
“It’s published both as a prediction and because it does tell the rest of the medical community, ‘Hey, look at these things,'” Roizen said. “The Cleveland Clinic, we’re lucky enough to be large enough, on the forefront (and) located in a real medical complex city where innovation is fostered. So this is essentially getting together some of the best minds. And then it alerts the rest of medicine we think this is going to make a change.”
Here, in order of anticipated importance, are descriptions of the Top 10 Medical Innovations of 2018, according to a news release from the Clinic.
1. Hybrid Closed Loop Insulin Delivery System
A hybrid closed loop insulin delivery system, approved by the FDA in late 2016, helps make Type 1 diabetes more manageable by enabling direct communication between the continuous glucose monitoring device and insulin pump. It stabilizes blood glucose at an unprecedented level and replaces the “open loop” concept in which patients use the information from their monitor to determine how much insulin to inject. Experts are optimistic that outcomes in Type 1 diabetes will push forward a similar product for Type 2 diabetes in the “near future.”
“I think it’s a great number one pick that’s going to have a dramatic impact on diabetes management in my opinion,” said Dr. James Young, chairman of the Clinic’s Endocrinology and Metabolism Institute.
The Clinic predicts the market will be disrupted in 2018 as more patients demand the technology and more insurers reimburse for the system.
2. Controlled by a remote or wearable patch, the technology delivers stimulation to open key airway muscles during sleep.
The neuromodulation systems have shown positive results in clinical testing and are predicted to deliver a better night’s sleep to more patients and spouses, as well as healthier communities nationwide.
3. Gene Therapy for Inherited Retinal Diseases
The FDA is anticipated to approve a new gene therapy for inherited retinal diseases in 2018. Delivering a new gene to targeted cells in the body, via viral “vectors,” is expected to provide visual function improvements in some patients with forms of Leber congenital amaurosis and retinitis pigmentosa.
Caused by biallelic RPE65 mutations, these rare genetic conditions result in progressive vision loss and blindness,
but there are currently no FDA approved treatments.
Researchers place a new “normal” working copy of a gene, which results in a functional protein, inside a modified virus that delivers it to retinal cells.
This year, the FDA awarded orphan drug status to RPE65 gene therapy. health advisers recently recommended approval for the innovative approach, which experts believe could lead to more gene therapies getting orphan drug and breakthrough status.
4. The Unprecedented Reduction of LDL Cholesterol
New drug combinations can help lower by 75% levels of low density lipoprotein (“LDL”) cholesterol, known as bad cholesterol, that brings fatty deposits that can clog arteries.
There are more than 400,000 coronary disease deaths and 102 million Americans live with high cholesterol levels.
While some patients and doctors wonder how low is too low, the floor is yet to be found following a number of trials that have been in progress testing this theory. New studies report a 20% reduction in the risk of cardiovascular death, myocardial infarction or stroke for patients who took statins combined with a new class of cholesterol lowering drugs (PCSK9 inhibitors) to reach ultra low LDL levels.
5. The Emergence of Distance Health
Removing geographic barriers to care can result in timelier, more efficient/optimal outcomes and significant cost savings. Distance health technologies, or telehealth, can enable care for both the physically challenged and those most vulnerable to infection.
Increased connectivity, thanks to mobile technology and consumer demand, mean hospitals are preparing for widespread adoption in 2018. Ninety percent of health care executives reported to have or are currently building a telehealth program. Reports predict 7 million patient users in 2018, a 19 fold increase from 2013.
Technology is expanding beyond the two way video platform, with patients now equipped with attachable devices that record and report medical information to doctors monitoring their condition. More than 19 million patients are projected to use such remote monitoring devices next year.
6. Next Generation Vaccine Platforms
In 2018, innovators will be upgrading the entire vaccine infrastructure to support the rapid development of new vaccines and breaking ground on novel mechanisms to deliver new and existing vaccines to broad populations.